Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial [Untersuchung der natürlichen Killer (NK-) Zellen in Patienten mit Multipler Sklerose unter Fingolimod-Behandlung: Eine monozentrische, prospektive, offene, einarmige Studie]

Trial Profile

Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial [Untersuchung der natürlichen Killer (NK-) Zellen in Patienten mit Multipler Sklerose unter Fingolimod-Behandlung: Eine monozentrische, prospektive, offene, einarmige Studie]

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Dec 2016

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Dec 2016 Planned End Date changed from 1 Mar 2016 to 1 Nov 2017.
    • 20 Dec 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top